{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T02:16:19Z","timestamp":1769220979184,"version":"3.49.0"},"reference-count":21,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1016\/j.ejca.2022.04.007","type":"journal-article","created":{"date-parts":[[2022,5,26]],"date-time":"2022-05-26T18:32:58Z","timestamp":1653589978000},"page":"131-139","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Survival after high-dose chemotherapy for refractory and recurrent Ewing sarcoma"],"prefix":"10.1016","volume":"170","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9614-0811","authenticated-orcid":false,"given":"Rachael","family":"Windsor","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony","family":"Hamilton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne","family":"McTiernan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Palma","family":"Dileo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Michelagnoli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beatrice","family":"Seddon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra J.","family":"Strauss","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6793-5722","authenticated-orcid":false,"given":"Jeremy","family":"Whelan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"20","key":"10.1016\/j.ejca.2022.04.007_bib1","doi-asserted-by":"crossref","first-page":"3284","DOI":"10.1200\/JCO.2009.22.9864","article-title":"Primary disseminated multifocal ewing sarcoma: results of the euro-EWING 99 trial","volume":"28","author":"Ladenstein","year":"2010","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.ejca.2022.04.007_bib2","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1002\/pbc.21618","article-title":"Prognostic factors for patients with ewing sarcoma (EWS) at first recurrence following multimodality therapy \u2013 a report from the children\u2019s oncology group","volume":"51","author":"Leavey","year":"2008","journal-title":"Pediatr Blood Cancer"},{"issue":"4","key":"10.1016\/j.ejca.2022.04.007_bib3","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1002\/pbc.23040","article-title":"Risk of recurrence and survival after relapse in patients with Ewing sarcoma","volume":"57","author":"Stahl","year":"2011","journal-title":"Pediatr Blood Cancer"},{"issue":"7","key":"10.1016\/j.ejca.2022.04.007_bib4","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1080\/0284186X.2018.1449250","article-title":"Irinotecan and temozolomide in recurrent Ewing sarcoma: an analysis in 51 adult and pediatric patients","volume":"57","author":"Palmerini","year":"2018","journal-title":"Acta Oncol"},{"key":"10.1016\/j.ejca.2022.04.007_bib5","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1186\/1471-2407-14-622","article-title":"A study of docetaxel and irinotecan in children and young adults with recurrent or refractory Ewing sarcoma family of tumors","volume":"14","author":"Yoon","year":"2014","journal-title":"BMC Cancer"},{"issue":"10","key":"10.1016\/j.ejca.2022.04.007_bib6","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1002\/pbc.24621","article-title":"Vincristine, irinotecan, and temozolomide in patients with relapsed and refractory Ewing sarcoma","volume":"60","author":"Raciborska","year":"2013","journal-title":"Pediatr Blood Cancer"},{"issue":"3","key":"10.1016\/j.ejca.2022.04.007_bib7","doi-asserted-by":"crossref","first-page":"170","DOI":"10.3109\/08880018.2013.767868","article-title":"A modified protocol with vincristine, topotecan, and cyclophosphamide for recurrent\/progressive ewing sarcoma family tumors","volume":"30","author":"Kebudi","year":"2013","journal-title":"Pediatr Hematol Oncol"},{"key":"10.1016\/j.ejca.2022.04.007_bib8","doi-asserted-by":"crossref","unstructured":"EuroEwingConsortium rEECur - International Randomised controlled trial of chemotherapy for the treatment of recurrent and primary refractory Ewing sarcoma. McCabe M. Results of the second interim assessment of rEECur, an international randomized controlled trial of chemotherapy for the treatment of recurrent and primary refractory Ewing sarcoma (RR-ES), J Clin Oncol. 38. 11502\u201311502. DOI: 10.1200\/JCO.2020.38.15 suppl.11502, no. 15 suppl (May 20, 2020).","DOI":"10.1200\/JCO.2020.38.15_suppl.11502"},{"issue":"31","key":"10.1016\/j.ejca.2022.04.007_bib9","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2018.78.2516","article-title":"High-dose chemotherapy and blood autologous stem-cell rescue compared with standard chemotherapy in localized high-risk ewing sarcoma: results of euro-E.W.I.N.G.99 and ewing-2008","volume":"36","author":"Whelan","year":"2018","journal-title":"J Clin Oncol"},{"issue":"34","key":"10.1016\/j.ejca.2022.04.007_bib10","doi-asserted-by":"crossref","first-page":"3192","DOI":"10.1200\/JCO.19.00915","article-title":"High-dose chemotherapy compared with standard chemotherapy and lung radiation in ewing sarcoma with pulmonary metastases: results of the European ewing tumour working initiative of national groups, 99 trial and EWING 2008","volume":"37","author":"Dirksen","year":"2019","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.ejca.2022.04.007_bib11","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1093\/annonc\/mdl108","article-title":"High dose chemotherapy with bone marrow or peripheral stem cell rescue is an effective treatment option for patients with relapsed or progressive Ewing\u2019s sarcoma family of tumours","volume":"17","author":"McTiernan","year":"2006","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2022.04.007_bib12","series-title":"Improving outcomes after relapse in Ewing\u2019s sarcoma: analysis of 114 patients from a single institution","first-page":"83548","author":"McTiernan","year":"2006"},{"key":"10.1016\/j.ejca.2022.04.007_bib13","series-title":"Role of high-dose chemotherapy and autologous hematopoietic cell transplantation for children and young adults with relapsed Ewing\u2019s sarcoma: a systematic review","author":"Tenneti","year":"2018"},{"issue":"8","key":"10.1016\/j.ejca.2022.04.007_bib14","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1002\/pbc.25042","article-title":"The value of high-dose chemotherapy in patients with first relapsed Ewing sarcoma","volume":"61","author":"Rasper","year":"2014","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.ejca.2022.04.007_bib15","doi-asserted-by":"crossref","first-page":"354","DOI":"10.3892\/ol.2021.12615","article-title":"Extraskeletal ewing sarcoma: diagnosis, management and prognosis (review)","volume":"21","author":"Abboud","year":"2021","journal-title":"Oncol Lett"},{"issue":"1","key":"10.1016\/j.ejca.2022.04.007_bib16","doi-asserted-by":"crossref","first-page":"22723","DOI":"10.1038\/s41598-021-02134-0","article-title":"A SEER-based nomogram accurately predicts prognosis in Ewing\u2019s sarcoma","volume":"11","author":"Zhan","year":"2021","journal-title":"Sci Rep"},{"issue":"6","key":"10.1016\/j.ejca.2022.04.007_bib17","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1002\/pbc.25388","article-title":"Post-relapse survival in patients with Ewing sarcoma","volume":"62","author":"Ferrari","year":"2015","journal-title":"Pediatr Blood Cancer"},{"issue":"11","key":"10.1016\/j.ejca.2022.04.007_bib18","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1093\/annonc\/mdg457","article-title":"Therapy and survival after recurrence of Ewing\u2019s tumors: the Rizzoli experience in 195 patients treated with adjuvant and neoadjuvant chemotherapy from 1979 to 1997","volume":"14","author":"Bacci","year":"2003","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2022.04.007_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbmt.2020.09.029","article-title":"Long-term follow-up of high-dose chemotherapy with autologous stem cell transplantation in children and young adults with metastatic or relapsed ewing sarcoma: a single-institution experience","volume":"27","author":"Pawlowska","year":"2021","journal-title":"Transplant Cell Ther"},{"issue":"19","key":"10.1016\/j.ejca.2022.04.007_bib20","doi-asserted-by":"crossref","first-page":"4354","DOI":"10.1200\/JCO.2005.05.105","article-title":"Survival after recurrence of Ewing\u2019s Sarcoma family of tumors","volume":"23","author":"Barker","year":"2005","journal-title":"J Clin Oncol"},{"issue":"14","key":"10.1016\/j.ejca.2022.04.007_bib21","doi-asserted-by":"crossref","first-page":"2384","DOI":"10.1200\/JCO.2007.14.7207","article-title":"Prognostic factors in metastatic rhabdomyosarcomas: results of a pooled analysis from United States and European cooperative groups","volume":"26","author":"Oberlin","year":"2008","journal-title":"J Clin Oncol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804922002088?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804922002088?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:37:08Z","timestamp":1760733428000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804922002088"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":21,"alternative-id":["S0959804922002088"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2022.04.007","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Survival after high-dose chemotherapy for refractory and recurrent Ewing sarcoma","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2022.04.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2022 Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}